Navigation Links
Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin Inhibitor
Date:6/12/2013

or efficacy when combined with well characterized agents for cancer immunotherapy," said Dr. Redmond, Assistant Member at the EACRI. "The experimental tumor models used are relatively resistant to therapy to checkpoint blockade inhibitors alone, indicating that the addition of GR-MD-02 may be a potentially important agent in combination therapy."

"We have determined that these pre-clinical results are compelling for clinical translation and we are planning to seek FDA agreement to open a trial using YERVOY™ (ipilimumab, anti-CTLA-4 mAb, BMS) in combination with GR-MD-02 in patients with advanced melanoma," said Brendan Curti, MD, Medical Oncologist and Director of the Providence Biotherapy Program at EACRI. "We are in the process of designing such a trial with Galectin Therapeutics."

Initial data was reported at the Tumor Immunology Keystone Conference in March of 2013 which showed that treatment with GR-MD-02 augmented CD8+ T-cell function in mice (poster available on Galectin web site: http://bit.ly/19gmjHX) These data show that in response to vaccination with an antigenic protein, inhibition of extracellular galectin-3 with GR-MD-02 increases the T-cell response to vaccination. Data was then obtained in several syngeneic tumor models in mice to evaluate the efficacy of anti-CTLA-4 and anti-PD1 monoclonal antibodies alone and in combination with GR-MD-02. As shown below, the addition of GR-MD-02 resulted in augmented tumor shrinkage in both prostate and breast cancer models.

(Photo: http://photos.prnewswire.com/prnh/20130612/DC30477)

These data were presented as part of the annual stockholder meeting on May 23, 2013 which can be viewed on the Galectin Therapeutics website (http://bit.ly/11QKp2P). 

Notes to the reader:  Checkpoint Blockade<
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
4. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
5. Bayer Submits New Drug Application for Regorafenib for the Treatment of Gastrointestinal Stromal Tumors (GIST)
6. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
7. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
8. ClearCanvas Platform Powers Tumor Imaging Metrics Core Measurements
9. Innovative CA Tumor Marker Tests Technologies and Emerging Markets
10. Lo screening trial sul cancro al seno conclude che lutilizzo della mammografia 3D in combinazione con un esame del seno 2D rileva un numero di tumori significativamente maggiore rispetto al solo esame del seno 2D
11. La nuova tecnologia Elekta per la radioterapia oncologica ridefinirà il futuro della lotta contro i tumori
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 Although lung ... the world, there are only 18 drugs in the ... Almita and Avastin are nearing their patent expiry in ... therapeutics market offers vast potential that drug manufacturers are ... treatment of small cell lung cancer (SCLC) and non-small ...
(Date:3/3/2015)... , March 3, 2015 ImmunoCellular Therapeutics, ... Andrew Gengos , Chief Executive Officer of ImmunoCellular, will ... 27 th Annual ROTH Conference on Tuesday, March ... Hotel, Laguna Niguel , CA.   ... the ROTH presentation, please log on through a link ...
(Date:3/3/2015)... , March 3, 2015 Chrono Therapeutics ... an investment by Rock Health , the leading ... of Chrono,s SmartStop™ programmable transdermal drug delivery system and ... Smoking kills more than 500,000 Americans each year, ... in the United States . Of ...
Breaking Medicine Technology:Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments 2Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments 3ImmunoCellular Therapeutics to Present at ROTH Conference on March 10th 2Chrono Therapeutics Receives Investment from Rock Health to Advance SmartStopTM Smoking Cessation Technology 2Chrono Therapeutics Receives Investment from Rock Health to Advance SmartStopTM Smoking Cessation Technology 3
... N.J., Sept. 28 Laureate Pharma, Inc., ... company, today announced the appointment of Steven ... Mr. Johnson will be responsible for Laureate,s ... business development and project management, supporting the ...
... JUNCTION, N.J., Sept. 28 Tamir Biotechnology, Inc. ... Corporation) announced today that scientists supported by the ... reported test results confirming two of our lead ... cell culture and plaque reduction assay (the gold ...
Cached Medicine Technology:Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development 2New Discovery Targets Cytomegalovirus (CMV) 2New Discovery Targets Cytomegalovirus (CMV) 3New Discovery Targets Cytomegalovirus (CMV) 4
(Date:3/3/2015)... Prophecy Healthcare®, Inc., the nation's ... testing, is now conducting dedicated research to expand ... of acquiring the exam rights and Intellectual Property ... the research will soon create more health care ... healthcare staffing organizations and more. , ...
(Date:3/3/2015)... 2015 Extend Nutrition, a leading nutritional snack ... of calories consumed at the next meal by an average ... are no lifestyle changes needed and no program to abide ... , The starter kit contains 60 servings of nutritional bars, ... protein, fiber, healthy fat and complex carbohydrates that helps to ...
(Date:3/3/2015)... 03, 2015 Getting to the truth of ... and well-being are at stake. So when it comes to ... move about pain-free – it’s vital to separate fact from ... resource, according to Sridhar Yalamanchili, PT, MSPT, and Director of ... A September 2014 nationwide survey by the American Physical Therapy ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Human ... that it’s offering a new master health insurance plan ... its clients with a group platform removing potential cost ... Master Health Plan has been in effect since January ... clients with much need medical cost savings. , The ...
(Date:3/3/2015)... Sponsors of Medicare Advantage (MA) plans and stand-alone ... changes to sift through as a result of CMS’s ... Feb. 20. The potential pay changes alone are tough ... type and location of the plan’s membership. But there ... before CMS issues the final notice and when 2016 ...
Breaking Medicine News(10 mins):Health News:Prophecy Healthcare Acquires IP to Expand Behavioral Benchmarks 2Health News:Prophecy Healthcare Acquires IP to Expand Behavioral Benchmarks 3Health News:Snack Your Way to a Smaller Waistline with Extend Nutrition’s New “Snack-2-Health Kit” 2Health News:Snack Your Way to a Smaller Waistline with Extend Nutrition’s New “Snack-2-Health Kit” 3Health News:Separating Fact from Fiction about Physical Therapy 2Health News:Separating Fact from Fiction about Physical Therapy 3Health News:HCBR Group Offers Master Healthcare Plan through Humana 2Health News:March 12 Webinar to Analyze Implications of CMS’s ’45-Day Notice’ and 2016 Call Letter for MA and Part D Plans 2
... PORTLAND, Ore. Researchers at Oregon Health & Science University,s ... women at high-risk for ovarian cancer who also want to ... which serve as the "breeding ground" for ovarian cancer, may ... would be a vast improvement over the current prevention strategy ...
... HealthDay Reporter , WEDNESDAY, April 6 (HealthDay News) ... not to mention the Grim Reaper, a new study from ... go shopping daily live longer than their less shopping-prone peers. ... women, according to the study, which was published recently in ...
... TORONTO, Ont., April 7, 2011 Virtual reality and other ... according to research from St. Michael,s Hospital. Patients ... up to five times more likely to show improvements in ... "Virtual reality gaming is a promising and potentially ...
... doctors more accountable for health care quality, more attention must ... to evaluate caregivers, says a prominent Johns Hopkins patient safety ... Health Affairs , Peter J. Pronovost, M.D., Ph.D., a ... Hopkins University School of Medicine, argues that as the desire ...
... Biology and Medicine is pleased to announce the 2011 ... $500 travel grant for undergraduate/ graduate students and/or individuals ... members of the Society to attend the Experimental Biology ... of their research work which were evaluated by a ...
... three-year follow-up study of patients in the Hepatitis ... revealed that increased mortality among patients with advanced ... was attributed to non-liver related causes and occurred ... to this excess mortality was evident to researchers, ...
Cached Medicine News:Health News:Ovarian cancer finding may be a 'win-win' for at-risk women who wish to have a family 2Health News:'Retail Therapy' Might Really Work 2Health News:'Retail Therapy' Might Really Work 3Health News:Video games effective treatment for stroke patients: study 2Health News:Unreliable 'outcomes' measures hamper efforts to assure better, safer care 2Health News:Unreliable 'outcomes' measures hamper efforts to assure better, safer care 3Health News:SEBM Young Investigator Awards for 2011 2Health News:Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis 2Health News:Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis 3
... Our most popular onsite test! QuickScreen multi-panel ... urine sample, and your choice of any ... multi-panels offer total flexibility for your drug ... the specimen and the built-in timer tells ...
... The SureStep™ Drug Screen Tests are available ... for MDMA (Ecstasy). Designed using Microgenics Antibody ... the only point of care immunoassay targeted ... for both MDA and MDEA but no ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... drugs of abuse tests are highly accurate in ... recommended cut-off as confirmed by GC/MS testing. This ... specific alternative method (such as GC/MS) must be ... Professional judgment should be applied to any drug ...
Medicine Products: